Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 29:15:875-883.
doi: 10.2147/JAA.S369836. eCollection 2022.

Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments

Laren D Tan  1   2 , Nolan Nguyen  3 , Abdullah Alismail  2 , Mario Castro  4
Affiliations
Review

Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments

Laren D Tan et al. J Asthma Allergy. .

Abstract

Asthma continues to be a complex respiratory disease to control for many despite optimal standard inhaler therapy. The increased dependence on steroid-sparing biologic treatments in the 21st century has created a dilemma between identifying the patient's intrinsic biomarkers and their "life markers." With Tezepelumab being the most recent FDA-approved biologic for asthma, it is even more critical for asthma specialists to better understand and establish a framework to determine which biologic would work best for their patients. While cost and payor approvals limit access to certain asthma biologics, medical decisions on which biologic to select should be centered around shared decision-making, the rationale for biologic initiation, and critical biologic education to help achieve successful asthma control.

Keywords: Tezepelumab; asthma; asthma biologic; severe asthma; shared decision making.

PubMed Disclaimer

Conflict of interest statement

Dr Mario Castro reports grants from NIH, grants from ALA, grants from PCORI, grants, personal fees from AstraZeneca, grants, personal fees from GSK, grants, personal fees from Novartis, grants from Pulmatrix, grants, personal fees from Sanofi-Aventis, grants from Shionogi, personal fees from Elsevier, personal fees from Genentech, personal fees from Teva, personal fees from Amgen, personal fees from Regeneron, during the conduct of the study. The authors report no other conflicts of interest in this work.

References

    1. Tan LD, Alismail A, Ariue B. Asthma guidelines: comparison of the national heart, lung, and blood institute expert panel report 4 with global initiative for asthma 2021. Curr Opin Pulm Med. 2022;28(3):234–244. doi:10.1097/MCP.0000000000000867 - DOI - PubMed
    1. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021;59(1):2102730. - PMC - PubMed
    1. Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112. doi:10.1164/rccm.201901-0016OC - DOI - PMC - PubMed
    1. Chipps BE, Murphy KR, Oppenheimer J. 2020 NAEPP guidelines update and GINA 2021-asthma care differences, overlap, and challenges. J Allergy Clin Immunol Pract. 2022;10(1S):S19–S30. doi:10.1016/j.jaip.2021.10.032 - DOI - PubMed
    1. Cloutier MM, Baptist AP, Blake KV; Expert Panel Working Group of the National Heart L, Blood Institute a, coordinated National Asthma E, et al. 2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:10.1016/j.jaci.2020.10.003 - DOI - PMC - PubMed